Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276) ; volume:13 ; number:4 ; day:8 ; month:11 ; year:2010 ; pages:1-2 ; date:12.2010
Journal of the International AIDS Society / International AIDS Society ; 13, Heft 4 (8.11.2010), 1-2, 12.2010
- Creator
-
Rockstroh, J.
- Contributor
-
Felizarta, F.
Maggiolo, F.
Pulido, F.
Stellbrink, HJ
Tsybakova, O.
Yeni, P.
Almond, S.
Brothers, C.
Song, I.
Min, S.
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-13-S4-O50
- URN
-
urn:nbn:de:1111-2016052058573
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rockstroh, J.
- Felizarta, F.
- Maggiolo, F.
- Pulido, F.
- Stellbrink, HJ
- Tsybakova, O.
- Yeni, P.
- Almond, S.
- Brothers, C.
- Song, I.
- Min, S.
- SpringerLink (Online service)
Other Objects (12)
O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults
Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study
The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)-containing once-daily highly active antiretroviral therapy (HAART)
Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial
Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation
Once-daily regimens were associated with a higher rate of self-chosen discontinuations
Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
The use of a darunavir/ritonavir once-daily regimen in two pregnant women
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults
Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study
The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)-containing once-daily highly active antiretroviral therapy (HAART)
Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial
Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation
Once-daily regimens were associated with a higher rate of self-chosen discontinuations
Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
The use of a darunavir/ritonavir once-daily regimen in two pregnant women
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults
Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study
The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)-containing once-daily highly active antiretroviral therapy (HAART)
Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial
Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation
Once-daily regimens were associated with a higher rate of self-chosen discontinuations
Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
The use of a darunavir/ritonavir once-daily regimen in two pregnant women